Clinical research

Clinical predictors of therapeutic response to antipsychotics in schizophrenia
Maren Carbon, MD; Christoph U. Correll, MD

Introduction

"No symptoms or syndromes at the time of onset could be used to predict, with any certainty, whatever the differentiation between malignant or benign process [...]" Huber and colleagues published this poignant notion 40 years ago in the context of a meticulous longitudinal study of 502 patients with schizophrenia, 75% of whom had been followed for 22 years. Despite having identified twelve major classes of courses of illness that to this date are still relevant (Figure 1A, B), the authors revert to a rather nihilistic statement regarding the possibility of predicting course and illness outcome for an individual patient. Since then, numerous additional longitudinal studies in schizophrenia have been conducted and reviewed without reaching consensus about consistent patterns of illness courses in schizophrenia beyond the notion of high heterogeneity and a high frequency of unfavorable outcomes. Nevertheless, several robust factors associated with poorer outcomes have been identified. These factors, which can be broadly categorized into modifiable and nonmodifiable predictors, are discussed in the following sections.
Clinical research

long-term outcome emerged from these studies: poor premorbid adjustment, male sex, earlier onset of disease, longer duration of the illness, and/or longer duration of untreated psychosis (DUP).

Using chronic patient cohorts to predict outcomes is complicated by factors that both increase heterogeneity and decrease generalizability: (i) Chronic patients have widely varying illness duration and prior treatment exposure; (ii) they are also self-selected for poorer outcome; (iii) information about premorbid and earlier illness phases are likely less reliable; and (iv) diagnostic classifications may change during long-term follow-up. First episode (FE) schizophrenia samples share at least a common starting point in their illness course, and are thus more suited to studying predictors of therapeutic outcomes.

Reviews of outcomes in FE psychosis concluded that up to 22% of subjects may recover within the first 5 years without further relapses. However, in subjects meeting full criteria for schizophrenia as opposed to other psychoses, relapse rates reach 80% to 85% during the first 5 years of illness. Even when limiting their overview to 21 studies with consistent criteria for schizophrenia (DSM-III, DSM-III-R, DSM-IV, ICD-10 schizophreniform, or schizoaffective disorders), wide variations were observed regarding remission (7% to 52%) or having a “chronic” course (34% to 57%) characterized by residual symptoms and/or relapses.

Ultra-long-term studies of schizophrenia are not only limited by feasibility aspects, but also by continued discussions about diagnostic boundaries, lack of a neurobiological definition of schizophrenia, drop-
outs that are not at random, and by limited knowledge of the untreated/natural disease course. Therefore, attention has shifted to studies aiming at understanding predictors of treatment response, remission, recovery and relapse, as markers of short- to mid-term prognosis (up to 5 years). Thus, even if we will not be able to identify reliable, modifiable, or outcome-relevant predictors of long-term results, we may be able to identify predictors for each phase of the disease course. Knowledge of prognostic factors may aid in identifying patient and treatment factors, and the interaction between the two that would help select treatments that are more likely to succeed, thereby avoiding multiple, unnecessary switches or treatment trials. If reliable predictors of response to different individual treatments could be found, this would enable stratified or individualized treatment in specific patient subgroups that likely differ biologically, leading to the observed heterogeneity of therapeutic response. Since relapses are a major source of individual suffering and societal cost of the illness, predictors of relapse have rightfully received attention. Although a recent meta-analysis identified medication nonadherence, depression, and substance use as the top three factors associated with relapse, except for the unequivocal role of nonadherence, results for all other predictors were heterogeneous and it has been emphasized that individual prediction of imminent relapse remains elusive. In this review, we have focused on response and remission (see definitions below), as relapse is not simply the inverse of reaching each of these steps. Furthermore, recovery, a concept that combines symptomatic remission with achieving certain functional levels, has received increasing attention. However, here we do not focus on recovery, as functional outcomes depend on psychosocial environment and interventions more than on current antipsychotic treatment, which can only provide a basis for additional nonpharmacologic interventions that can help patients achieve psychosocial, educational, and vocational goals. Although, ultimately, it will be necessary to combine clinical with neurobiological markers of diagnosis and outcomes, the scope of this review is limited to clinical predictors of therapeutic response and remission. Since, as mentioned, FE samples have advantages for identifying more generalizable and reliable correlates of short- and medium-term outcomes, we focus on FE studies wherever possible.

**Methods**

Literature for this review was identified by searching PubMed, using the terms schizophrenia or psychosis and outcome or response or remission, and by manual searches of reference lists of relevant publications. Due to the wealth of outcome studies in schizophrenia that used very heterogeneous designs and outcome definitions, we refrained from a systematic review and meta-analysis. Instead, we gave weight to the most recent reviews, updating the evidence by relevant studies published since 2006. Due to the methodological limitations discussed above, we focused on FE psychosis, using additional data from work in chronic schizophrenia for specific aspects, including treatment-refractory schizophrenia and areas with relevant differences between FE and multi-episode schizophrenia. Moreover, to avoid the methodological limitations of ultra-long-term studies, we focused on studies with up to 5 years’ follow-up.

**Definitions of key elements of the outcome pathway**

The American Psychiatric Association’s Practice Guideline for Schizophrenia treatment defines phases of response to treatment as taking 1 to 2 years in order to move from the acute phase, through the stabilization and stable phase, to the recovery period, if not interrupted by relapse. Dissecting this dynamic process into defined sub-periods is artificial, but necessary to consider manageable, informative time frames. However, the terms response, remission, recovery, and even relapse have been used inconsistently. Thresholds and operational definitions for these illness phases have been reviewed and discussed, but consensus for all terms is missing. In addition to the physicians’ perspective, recent work also highlighted the importance of the patients’ perspective, adding subjective well-being and quality of life as important outcome targets. Although these subjective and functional outcome dimensions are highly important, pragmatic reasons limit the present review to predictors of response and remission.

*Figure* 2 summarizes the main illness phases with estimates of the frequency of patients with schizophrenia being in or transitioning to these respective illness phases, recognizing that individual samples, definitions, and time frames differed considerably.
**Response** is a relative term, defining a clinically significant improvement of a subject’s global psychopathology, irrespective of whether or not the subject continues to have specific symptoms. In clinical trials, thresholds for response have sometimes been arbitrarily defined. Although clear agreement regarding accepted cutoffs is missing, a proportion of symptom reduction is generally defined. Treatment response is a key determinant of subsequent outcome, as it is an essential precondition for remission and recovery, being closely related to treatment continuation. However, using cutoffs omits informative value of continuous data, reducing the variable spectrum of individual illness pathways to a binary result. Using equipercentile linking of percentage improvement in the Brief Psychiatric Rating Scale (BPRS)/Positive and Negative Syndrome Scale (PANSS) with improvement in the Clinical Global Impressions improvement (CGI-I) scale, Levine and colleagues showed that a 20% to 25% reduction of the BPRS/PANSS baseline score corresponded to minimal improvement on the CGI-I, whereas a 40% to 50% reduction corresponded to “much improved.” Since many acutely ill patients with schizophrenia often respond well to therapy, it was concluded that for acutely ill patients the 50% cutoff would be a clinically meaningful criterion. However, in chronic or treatment-resistant patients, even a small improvement might represent a clinically significant effect, justifying the use of the 20% to 25% cutoff in treatment-refractory patients. Therefore, the authors advocate for reporting results for multiple thresholds in the same study in order to display the entire range of response groups.

**Remission** is an absolute term defined as the sustained absence of significant (but not necessarily all) clinical signs and symptoms, using various thresholds for remaining symptoms prior to the consensus definition by the Schizophrenia work group. This workgroup defined “remission” by a rating of key positive and negative symptoms at a level of “mild” or less, which needs to be maintained for ≥6 months. Despite existing consensus criteria for remission, this definition is currently not used consistently, but the term remission is often used as a cross-sectional criterion for the presence of mild symptoms (Table I).
To interpret the clinical remission criteria within the context of the patient’s life, outcome studies also studied functional/psychosocial remission, and both terms have been used to define favorable outcome separately or in combination. The earlier longitudinal outcome studies stratified subgroups according to functional outcomes, and considered being employed at least part-time at or closely below the premorbid occupational level a favorable outcome. For the purpose of this paper, we used the term “sustained remission” whenever the workgroup criteria were used correctly, requiring the period criterion of 6 months; when the time criterion was dropped, we used the term “cross-sectional remission.”

Recovery is an outcome domain that combines symptomatic remission with a minimum of self-care, social and education/vocational functioning that are all sustained for at least 2 years.19,20,22

Results

Across FE studies of schizophrenia-spectrum disorders, response rates varied from 40% at 16 weeks of antipsychotic treatment to 81% and even 87% at 1 year, with a cluster around 50% within the first year of treatment (see Table II for frequencies and predictors by study). Remission rates vary more, even in studies using standardized remission criteria,33 with rates as low as 17% for haloperidol in the European First-Episode Schizophrenia study35 to rates as high as 81% in a Chinese First-Episode study,39 with several studies ranging around 35% to 50% to 87%33 (Table II). Significant patient, illness, treatment and environmental predictors are listed in Table III. Only those that emerged repeatedly are summarized below.

| Dimension of psychopathology | DSM-IV criterion | Scale for Assessment of Positive Symptoms (SAPS) and Scale for Assessment of Negative Symptoms (SANS) items | Positive and Negative Syndrome Scale (PANSS) items | Brief Psychiatric Rating Scale (BPRS) items |
|-----------------------------|------------------|-------------------------------------------------------------------------------------------------|-----------------------------------------------|---------------------------------------------|
| Psychoticism (reality, distortion) | Delusions | Delusions (SAPS) 20 | Delusions (SAPS) 7 | Delusions Unusual thought content Hallucinatory behavior P1 8 |
| | Hallucinations | Hallucinations (SAPS) 20 | | | Suspiciousness P9 11 |
| | | | Unusual thought content Hallucinatory behavior P3 15 | | |
| | | | | Grandiosity | |
| | | | | Suspiciousness | |
| | | | | Unusual thought content Hallucinatory behavior | |
| | | | | | |
| Disorganization | Disorganized speech | Positive formal thought disorder (SAPS) 34 | Conceptual disorganization Mannerisms/posturing P2 4 |
| | Grossly disorganized or catatonic behavior | Bizarre behavior (SAPS) 25 | | Mannerisms/posturing G5 7 |
| | | | | |
| | | | | |
| Negative symptoms (psychomotor poverty) | Negative symptoms | Affective flattening (SANS) 7 | Blunted effect N1 16 |
| | | Avolition-apathy (SANS) 17 | Social withdrawal N4 17 |
| | | Anhedonia-asociality (SANS) 22 | No clearly related symptom N6 17 |
| | | Alogia (SANS) 13 | |
| | | | |
| | | | |

Table I. Proposed items for remission criteria as defined by the Remission in Schizophrenia Working Group.28 a For symptomatic remission, maintenance over a 6-month period of simultaneous ratings of mild or less on all items is required. Rating scale items are listed by item number. b Use of BPRS criteria may be complemented by use of the SANS criteria for evaluating overall remission. The PANSS scale is the simplest instrument on which a definition of symptom remission can be practically based. DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition
**Clinical research**

| Study                        | Outcome                      | Cohort; measures                                                                 | Outcome rates – baseline/clinical predictors for outcome as reported by the study                                                                 |
|------------------------------|------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Addington & Addington 2008   | Sustained remission          | 240 FE SCZ spectrum disorder or other psychotic disorder PANSS; 6 monthly up to 36 months | 36.7% achieved sustained remission. Additional 20.4% achieved cross-sectional remission at some point. Nonremitters (23.3%): lower baseline GAF, worse insight, higher positive and/or negative symptom score, reduced social functioning, lower premorbid functioning, longer DUP |
| Agid 2011                    | Response CGI-I = 1-2 and/or BPRS Thought Disorder subscale score ≤6 | 244 subjects with FE SCZ or schizoaffective disorder, followed through up to 3 treatment trials (each 12 weeks) to determine treatment rates in subsequent treatment trials | 1st trial response rate: 74.5% (olanzapine: 82.1%; risperidone: 66.3%; P<0.01); 2nd trial, response rate 16.6% (olanzapine: 25.7%; risperidone: 4.0%). 3rd trial; response rate: 75.0% (clozapine) |
| Albert 2011                  | Recovery (symptomatic remission + occupational + social functioning) | 255 FE psychosis; 5 years                                                          | 15.7% recovery, but ≤50% of these had achieved recovery within 2 years. 29.8% professionally occupied. Predictors of recovery: female, higher age, good premorbid function, stable social environment |
| Boter 2009                   | Sustained remission          | 498 FE SCZ (EUFEST) schizoaffective, or schizoaffective disorder; PANSS 12 months follow-up | Response/ remission rates varied with antipsychotic from 37%/17% (haloperidol) to 67%/40% (amisulpride or olanzapine). Predictors for response: adherence, more severe baseline psychopathology, treatment with amisulpride. Predictors for remission: adherence, treatment with amisulpride or olanzapine, no current substance use disorder |
| Chang 2011                   | Intermediate-term Outcome    | 93 SCZ, schizophreniform, schizoaffective; SANS, HEN f. negative symptoms; 3 years follow-up | Comparison of subjects with/without persistent primary negative symptoms: clinical and cognitive baseline characteristics did not predict PPN at year 3 |
| Chang 2012                   | Sustained remission          | 700 FE psychosis SANS, 3 years                                                      | At 3 year end point 58.8% symptomatic remission. Logistic regression for symptomatic remission: female, older age at disease onset, shorter DUP and early treatment response |
| Crespo-Facorro 2007           | Response ≥40% BPRS reduction | 172 subjects with FE SCZ spectrum; BPRS, SAPS, SANS, CGI; 6 weeks                  | 57.8% response. Predictors of poor response: diagnosis of SCZ, young age of onset, poor premorbid adolescent adjustment, lower BL BPRS |
| Crespo-Facorro 2013           | Response at 6 weeks (≥40% BPRS reduction + CGI total score of ≤4) | 375 FE BRP, SCZ, schizoaffective disorder, schizoaffective disorder; BPRS, SAPS, SANS, CGI weekly. 6 weeks | 53.3% response rate. Predictors of poor response: lower severity of BL symptoms, diagnosis of SCZ; longer DUP, poorer premorbid adjustment, family history of psychosis, hospitalization |
| Derks 2010                   | Sustained remission          | 498 subjects with FE SCZ, schizophreniform, schizoaffective; 12 months PANSS         | 59% sustained remission, 77% cross-sectional remission. Predictive early response (CGI mild) at week 2, but improved prediction based on 6-week data PPV (0.73), NPV (0.61). Lower odds for remission: male, BL akathisia, no early response, no remission at week 4 |

**Table II.** Studies reporting on response or remission and its predictors in patients with first episode (FE) psychosis (2006-06/2014). BRP, brief reactive psychosis; SCZ, schizophrenia; SADS-C +PD, Schedule for Affective Disorders and Schizophrenia Change Version with psychosis and disorganization items; PANSS, Positive and Negative Syndrome Scale; SAPS, Scale for the assessment of positive symptoms; SANS, Scale for the Assessment of Negative Symptoms; HEN, High Royds Evaluation of Negativity Scale; BPRS, Brief psychiatric rating scale; DUP, Duration of untreated Psychosis; GAF, Global Assessment of Functioning Scale; CGI, Clinical Global Impression
| Study                  | Outcome                  | Cohort; measures                                                                 | Outcome rates – baseline/clinical predictors for outcome as reported by the study                                                                 |
|-----------------------|--------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Diaz 2013<sup>48</sup> | Sustained remission      | 174 FE, BRP, schizophreniform disorder, SCZ, schizoaffective disorder, or psychosis NOS; BPRS, SAPS, SANS; Cognitive Measures; 1 year | 31% sustained remission at 1 year. Predictors of sustained remission: shorter DUP, lower BL negative symptoms, and complete primary education. Model predicted non-remission by 89.9%. Univariate characteristics of non-response: male, SCZ, single status, lower primary educational level |
| Emsley 2006<sup>41</sup> | Sustained remission      | 57 FE SCZ, schizophreniform or schizoaffective disorder PANSS; 24 months          | 70% cross-sectional remission. 33% sustained remission. Multivariate model predicting 86% of nonremitters: presence of neurologic soft signs, DUP>1 year, marital status, and high PANSS excited/hostility factor score at baseline. Nonremitters at 2 years had lower % PANSS reduction at week 6 |
| Emsley 2007<sup>42</sup> | Sustained remission      | 462 SCZ, schizophreniform or schizoaffective disorder PANSS; CGI; 2-4 years       | 70% cross-sectional remission criterion at some point; 23.6% sustained remission. Mean time until first remission 153 ± 173 days. Independent predictor of sustained remission: DUP 33% with ≤391 days DUP remitted, 18% with longer DUPs remitted |
| Gäbel 2014<sup>40</sup> | Sustained remission      | 166 subjects FE SCZ, past acute treatment period. GAF, PANSS (all at the beginning of the maintenance period); follow-up from month 12 to month 24 | 39.1% sustained remission, 27% no sustained remission. Predictors for cross-sectional remission (calculated from month 12 data not from baseline): lower positive, negative, and general symptoms, less psychological side effects of medication, better social functioning |
| Gallego 2011<sup>34</sup> | Cross-sectional remission | 112 FE SCZ, schizophreniform or schizoaffective disorder SADS-C + PD; 16 weeks. | Cumulative response: 39.59% (week 8); 65.19% (week 16), rates increased 5% per 2 weeks. Relative reduction in symptom severity at week 4 (but not 2 or 8) was associated with responder status at week 16 |
| Johnson 2012<sup>51</sup> | Cross-sectional remission | 95 FE SCHZ subjects followed at 6, 12, 60 months PANSS, GAF, BPRS | 68.4% cross-sectional remission. 14.7% returned to premorbid level of functioning. Predictors for remission: urbanicity, fluctuating course. Negative correlation of BPRS and insight scores at year 5, but in multivariate models the patients’ understanding of illness had relatively low impact |
| Lambert 2008<sup>53</sup> | Recovery: Sustained symptomatic (CGI-SCH <3 ) + functional remission (occupation +independent + social). | 392 FE SCZ (European SOHO study subgroup) PANSS, CGI; 3 years, | 3-year rates for symptomatic/ functional remission: 60.3%/45.4%. 48.9% of subjects with combined sustained remission had adequate subjective well-being. 65.3% of subjects with symptomatic and functional remission at 3 months recovered, while only 10.0% of early non-remitted cases did. Predictors of recovery at end point: baseline functional status and early remission (during first 3 months) |
| Levine and Rabinowitz 2010<sup>43</sup> | Response trajectories    | 49 FE with SCZ, schizoaffective (recent onset, <60 month) PANSS, 6 months       | 5-trajectory solution fitted data best (mixed mode latent regression). Poor response (14.5%): younger age of onset, lower BL scores on cognitive testing. Best response (17.1%): good premorbid function, higher BL scores on cognitive testing, no diagnosis of SCZ |
| Study                  | Outcome                  | Cohort; measures                                                                 | Outcome rates – baseline/clinical predictors for outcome as reported by the study                                                                 |
|-----------------------|--------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Levine 2010^54        | Response trajectories    | 263 subjects with SCZ, schizoaffective disorder (recent onset, <60 month). PANSS, 2 years | 5-trajectory solution: The most improved trajectory group (22.9%), showed improvement until week 16 + subsequent stability. Characteristics of best response subgroup: no diagnosis of SCZ, good premorbid adjustment, lower BL PANSS |
| Malla 2006^15         | Remission (cross-sectional) | 107 FE SCZ patients; 2 years                                                      | 82.2% in remission. Positive predictors for remission: better pre-morbid adjustment, later age of onset, higher level of adherence to medication and shorter DUP |
| Nordon 2014^58        | Clinical response (CGI-S score <4 and ≥30% improvement) | 467 with antipsychotic-naive schizophrenia (mean baseline treated illness duration 2.7 years, moderately delusional thoughts = exclusion) CGI-S; 6 months | 53.3% responders; 5 trajectories: 43.6% "gradual response", 28.5% "remaining mildly ill," 13.3%: "unsustained improvement," 9.6% "rapid response." Predictor of good 6-month response: high baseline CGI, low level of negative symptoms Clinical improvement at 1 month predicted 6-month outcome |
| Pelayo-Teran 2014^16  | Response trajectories    | 161 FE schizophreniform disorder, schizoaffective disorder, BRP. SAPS, SANS, 6 weeks | 5-trajectory solution for positive symptom response, 3 trajectories for disorganization, 5 trajectories for negative symptoms. Clear divergence of trajectories as early as week 2. Predictors of poor response of positive symptoms: Longer DUPs, cannabis. Predictors of poor response of negative symptoms: only cannabis |
| Petersen 2008^57      | Remission (cross-sectional) Recovery (symptomatic remission plus occupied) | 369 FE SCZ-spectrum disorder SANS, SAPS, GAF 2 years follow-through | Remission: 35.8%; Recovery 17.9%; 43.9% of recovered subjects on AP; Predictors of poor recovery: longer DUP, medication non-adherence, BL negative symptoms, substance-use disorder |
| Saravanan 2010^58     | Remission (symptom-free for 30 days); Relapse | 131 FE SCZ; BPRS, GAF 6 + 12 months follow-up | Remission at 1 year: 50.4%, 12% relapse. Predictors of remission: shorter DUP, change in insight and in BPRS (6-12 months) |
| Schennach-Wolf 2011^17 | Response = ≥ 50% PANSS reduction Remission (cross-sectional) | 224 FE SCZ, PANSS, 8 week data. Early response = ≥ 30% PANSS total score reduction by week 2 | 52% response. Predictors for response: early response, higher BL PANSS positive subscore. Predictors for remission: shorter DUP, lower PANSS general, early treatment response |
| Seitten 2007^39       | Mid-term outcome         | 125 FE schizophreniform-disorder; incidence study, 30 months follow-up             | 56% poor outcome. Male sex in conjunction with substance abuse (cannabis) as predominant predictor of poor outcome. DUP failed to reach significance |
| Simonsen 2010^68      | Remission at 3 months and 2 years, with a definition of remission = 1 week without positive symptoms | 301 FE actively psychotic patients: SCZ, schizoaffective disorder, schizoaffective, BRP delusional disorder, affective psychosis with mood-incongruent psychotic features, psychotic disorder NOS; PANSS, GAF; 3 month, 2 year | 56.2% remission at 3 months, prolonged remission of positive symptoms: 68.7% DUP = only predictor for remission |

Table II. Continued
Patient variables

Reduced odds for response in FE schizophrenia samples were associated with poor premorbid adjustment and a positive family history for psychotic disorders (Table III).

| Study                  | Outcome                                      | Cohort; measures                              | Outcome rates – baselineclinical predictors for outcome as reported by the study |
|------------------------|----------------------------------------------|-----------------------------------------------|----------------------------------------------------------------------------------|
| Stauffer 2011          | Response (50% PANSS reduction)               | 225 FE SCZ, schizoaffective disorder PANSS, 12 weeks | 43.1% showed early response (defined as 26% reduction in PANSS) by week 2; and this was predictive for subsequent response |
|                        |                                              |                                               | No effect of age, gender, DUP                                                      |
| Stentebjerg-Olesen 2013| Response = CGI-I of ≤3                       | Adolescents, 58% male, SCZ, schizoaffective disorder, BRP, Psychosis NOS, CGI, 0-12 week | Week 4: 45.6% early response. Early response/early non-response predicted ultimate response/ultimate nonresponse (specificity of 85.3%). Predictors of early nonresponse: more EPS, higher age. Predictors of ultimate response: Early response, Psy NOS/brief psychotic disorder |
| Üçok 2011              | Sustained remission                          | 93 FE SCZ; Follow-up 1-12 Years (mean 4.8 years); Monthly BPRS, SANS, SAPS; focus first 24 months | 59.5% remission within 2 years, but 71.5% of these could not maintain sustained remission. 69% had at least one relapse during follow-up (up to 12 years). Remission predictors: Lower negative and higher positive symptoms at admission, lower positive symptoms at month 3 of follow-up, medication compliance in the first 6 months, and occupational status during the last month before admission |
| Ventura 2011           | Sustained remission (BPRS based analogous to Andreasen) Recovery (above + functional remission) | 77 FE SCZ, schizoaffective or schizophreniform disorder patients (83% male), on fluphenazine decanoate BPRS every 3 months; 12 months follow-through | 22% sustained remission at last follow-up, 36% remission for any 6-month period, 10% recovery. No association between symptom remission and good functional outcome (which was associated with baseline WAIS) |
| Verma 2012             | Response (40% PANSS reduction; Sustained remission + Functional remission (GAF≥60) = recovery | 1175 subjects with SCZ-spectrum disorder, BRP, affective psychosis, PANSS, GAF; 2 year | 3-month response: 45.6%; 2-year follow-up: 54.1% remission 29.4% symptomatic + functional remission at year 2. Predictors for remission and recovery: female, tertiary education, shorter DUP, early response at month 3, lower BL PANSS negative scores |
| Wunderink 2009         | Recovery (sustained symptomatic and functional remission) | 125 FE SCZ (with response to initial treatment; 48.6% of FE sample); PANSS; Follow-up: 9 months during the 2nd post-acute year | 52% symptomatic remission. 19.2% recovery; DUP and baseline social functioning independently predicted recovery. No recovery in subjects with DUP of ≥6 months |
| Zhang 2014             | Response ≥ 50% PANSS reduction Sustained remission | 398 FE; SCZ, acute schizophreniform disorder, never medicated, PANSS, 1 year | 70% responders at 1 year follow-up. Prediction of good response: shorter DUP, continuous treatment, higher BL general and subscale positive PANSS. 81.4% sustained remission: only DUP remained as independent factor (remitters: younger, less chronic prodromal phase, less family conflicts), relapse rate: 8.1% |

Table II. Continued
Clinical research

| Domain                                | Associated variable | Response | Remission |
|---------------------------------------|---------------------|----------|-----------|
| Patient variables                     |                     |          |           |
| Age                                   | None of the studies into response listed in table 2 found a significant effect of age. |          | Older (Zhang 2014,45 Albert 201144) |
| Sex                                   | Male: Rabinowitz 201475 |          | Male (Selten 2006,46 Derks 2010,47 Verma 2012,48 Diaz 2013,49 Albert 2011,44 Clemmensen 201250; early-onset schizophrenia) |
|                                       | No effect of sex in: Malla 2006,39 Emsley 2007,39 Lambert 2008,39 Levine 2010,39 Saravanan 2010,39 Simonsen 2010,39 Agid 2011,30 Schennach 2011,31 Ventura 2011,34 Uck 2011,36 Stentebjerg-Olesen 2013,32 Galderisi 2012,66 Wunderink 201339 |          | Female (clozapine: Nielsen 201242) |
| Premorbid adjustment                  | Poor (Malla 2006,35 Levine 2008,32 Levine 201052) | Poor (Addington and Addington 2008,40 Crespo-Facorro 2007,47 Albert 201144) |
| Educational level                     | Lower education (Verma 2012,45 Diaz 201349) |
| Marital status                        | Single (Emsley 2006,41 Diaz 201349) Married (Tefarra 201259) |
| Neurological soft signs               | Present (Emsley 200641) |
| Family history of psychosis           | Positive family history (Crespo-Facorro 201356) |
| Illness variables                     | Diagnosis           | Diagnosis of schizophrenia (Crespo-Facorro 2007,37 Levine and Rabinowitz 2010,34 Levine 201058) |
|                                       | Age of Illness Onset Younger age (Crespo-Facarro 2007,47 Seimiz 2007,7 Levine and Rabinowitz 2010,45 Rabinowitz 201475) | Younger age (Tef 2012)50 |
|                                       | Duration of untreated psychosis Longer DUP (Pelayo-Teran 2014,36 Zhang 201439) | Longer DUP (Emsley 2006,41 2007,42 Addington and Addington 2008,40 Jepeesen 2008,72 Malla 2006,35 Simonsen 2010,39 Saravanan 2010,39 Schennach-Wolf 2011,37 Kurihara 2011,37 Thirthalli 2011,38 Verma 2012,39 Diaz 2013,40 Pelayo-Teran 2014,36 Zhang 201439) |
|                                       | Illness duration    | Longer (Malla 2006,35 Rabinowitz 201475) | Longer (Clemmensen 201256; early onset schizophrenia) |
|                                       | Baseline total symptom severity Lower severity (Crespo-Facorro 2007,47 Boter 2009,48 Crespo-Facorro 2013,46 Zhang 2014,36 Rabinowitz 201475) | Higher severity (Addington & Addington 200850; Schennach-Wolf 201151; Johnson 201255; Diaz 201356; Gabel 201455) |
|                                       | Baseline positive symptoms Lower severity (Schennach-Wolf 2011,37 Zhang 201441) | Higher severity (Addington and Addington 200846, Učok 2011,43 Verma 201252 Diaz 201348 Gabel 201450) |
|                                       | Baseline negative symptoms | Higher severity (Addington and Addington 200846; Učok 2011,43 Verma 201252 Diaz 201348 Gabel 201450) |

Table III. Selected significant predictors for poorer response or lower likelihood of remission in FE schizophrenia samples and in selected chronic schizophrenia studies published since 2006.
Clinical predictors of response in schizophrenia - Carbon and Correll

Dialogues in Clinical Neuroscience - Vol 16 · No. 4 · 2014

not a characteristic of poor treatment response in the majority of more recently published studies using criteria for response and remission in the very early post-acute period, except for a large meta-analysis of placebo-controlled studies in chronic schizophrenia. Conversely, studies which confirmed a poorer outcome in males referred mostly to time frames of at least 1 year. This poorer outcome in longer-term studies may relate to the increased risk for relapse in males or to risk factors for relapse, which are overrepresented in males, including substance abuse, reduced help-seeking behavior, and increased baseline psychopathology.

Poor premorbid adjustment is a traditionally implied predictor of poor outcome that has largely been confirmed by current studies. Poor premorbid functioning may be a nonspecific marker of greater neurodevelopmental disturbance, which negatively impacts the outcome. This notion is supported by a large international study, in which subjects with good premorbid

| Domain                          | Associated variable | Response                                      | Remission                                      |
|---------------------------------|---------------------|------------------------------------------------|------------------------------------------------|
| Baseline general psychopathology|                     | Higher severity (Schennach-Wolf 2011, Gäbel 2014) |                                                |
| Baseline excited factor         |                     | Higher severity (Emsley 2006)                  |                                                |
| Baseline cognitive dysfunction  | Greater dysfunction (Levine and Rabinowitz 2010) | No effect of cognitive dysfunction (Chang 2011) |                                                |
| Insight                         |                     | Impaired insight (Johnson 2012) Less improved insight (Saravanan 2010) |                                                |
| Functional status               | General dysfunction (Nordon 2014) | Social dysfunction (Addington and Addington 2008, Gäbel 2014) Lack of professional occupation (Üçok 2011) |                                                |
| Comorbidities                   | Cannabis (Pelayo-Teran 2014): positive and negative symptom response | Substance Misuse (Selten 2006, Boter 2009) |                                                |
| Treatment variables             |                     |                                                |                                                |
| Antipsychotic Adherence         | Nonadherence (Malla 2006, Boter 2009, Zhang 2014) | Nonadherence (Üçok 2011); Functional remission: Dose reduction or discontinuation (Wunderink 2013) |                                                |
| Early treatment response/remission (at varying time points) | Early response (Levine 2010; Schennach-Wolf 2011, Stauffer 2011, Nordon 2014, clozapine: Semiz 2007, adolescents: Stentebjerg-Olesen 2013) | Early response/remission (Emsley 2006, Derks 2010, Gallego 2011, Schennach-Wolf 2011, Verma 2012) |                                                |
| Psychiatric hospitalization     | Hospitalized (Crespo-Facorro 2007) |                                                |                                                |
| Side effects                    | Parkinsonism (Stentebjerg-Olesen 2013) Baseline akathisia (Ders 2010) | Patient-rated psychological side effects, eg, tension, depression, emotional indifference (Gäbel 2014) |                                                |
| Environmental variables         |                     |                                                |                                                |
| Social support                  | More family conflict (Zhang 2014) |                                                |                                                |
| Rural environment               | Rural environment   |                                                |                                                |

Table III. Continued

515
functioning did not only achieve a more pronounced reduction in psychopathological measures, but required lower antipsychotic doses. Importantly, despite being slightly correlated, premorbid adjustment and DUP independently predict outcome. 30,31,67,77

Illness variables

Reduced odds for response in FE psychosis were related to the diagnosis of schizophrenia, younger age of illness onset, longer DUP and illness duration, and to lower positive or general psychopathology, greater cognitive dysfunction, lower functional status, and substance use (Table III).

Reduced odds for remission were significantly associated with longer DUP and illness duration, higher severity of all aspects of psychopathology (total, positive, negative, general psychopathology, and excited factor symptoms), impaired insight and functional status, as well as substance-use disorder (Table III).

The seeming paradox that higher psychopathology predicts a higher chance of response but lower odds of remission has to do with the fact that response is a relative term, while remission depends on falling below an absolute threshold. The higher chance of response has to do with the so-called “law of initial value hypothesis” (see ref 76). This “law” states that “the higher the initial value, the greater the organism’s response.” Treatment trajectories typically assume a hyperbolic decline function with major response gains over 2 to 4 weeks and relative leveling off thereafter, such that patients with higher initial psychopathology scores still remain above remission values while having reached the plateau period. In fact, more severe psychopathology at baseline reflects less amenable illness and consecutively low remission rates in FE12,29,40,41,49,50,54,57,63 and in chronic schizophrenia.85 By contrast, the lower the initial psychopathology score, the closer the patient is to reaching the remission threshold.

Negative symptoms have been confirmed as major predictors of poor outcome. 86-88 There is compelling evidence for a strong effect of negative symptoms on recovery and long-term functional outcomes 7,88,89 but a predictive value of baseline negative symptoms for the relative treatment response, conceptualized as a short-term marker of efficacy, has not been demonstrated. Conversely, sustained remission, as an intermediate marker of treatment efficacy, has been associated with less negative symptom loads.29,40,42,60,73 Likely, this observation reflects the close association between negative symptoms and measures of real-life functioning, such as interpersonal behavior, community activities, and work skills, 90,91 whereas proportional changes in PANSS, BPRS, or CGI may be dominated by positive symptoms during acute illness periods when treatment is often initiated. Thus, changes of sum scores fail to reflect the poor response of negative symptoms, as negative symptoms change relatively little with currently available treatments (see also trajectories for negative symptoms in refs 56, 76). However, this negative predictive value of greater negative symptom load may not apply to treatment with clozapine. Indeed, in a 4-month open study of treatment-resistant schizophrenia, higher baseline negative symptom severity was predictive for subsequent clozapine response.70

Earlier illness onset,71 especially during childhood and adolescence,92,93 has traditionally been implied as a negative prognostic factor, which is confirmed by current studies. Interestingly, however, recent data suggested similar outcomes in early-onset schizophrenia and adult-onset schizophrenia when the DUP is short.92,93 There is emerging evidence that the effect of earlier illness onset may, at least in part, be mediated by longer illness duration and higher number of relapses that have been associated with a diminution of treatment response.86,95 (see also below).

Response and remission rates were higher in studies including brief psychotic disorder and psychosis not otherwise specified (NOS).29,36,40,47,49,56,60,62,67 i.e., when less severely ill and impaired subjects and those with shorter illness duration drive better long-term outcomes. By contrast, poorer outcomes are associated with the diagnosis of schizophrenia (ICD-10- or DSM-IV-based, Tables II and III). To date, there are no published studies using DSM-5 criteria. However, despite a somewhat increased specificity of the criteria that now demand presence of two positive symptoms, applying DSM-5 is unlikely to significantly reduce the observed heterogeneity within patient groups diagnosed with schizophrenia.

Neurocognitive deficits have been well established in FE psychosis as independent disease characteristics in addition to positive and negative symptoms, but their effect on outcome parameters is less well understood. While several studies suggested an association of single neurocognitive measures and functional outcome parameters,96-103 a comprehensive synthesis of studies failed
to demonstrate consistent or specific associations. It is likely that this failure relates to the diversity of studied neurocognitive measures, which were typically correlated as single factors with specific outcome parameters. By contrast, analysis of the neurocognitive data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study demonstrated strong intercorrelations of neurocognitive domains. Moreover, neuropsychological testing requires a basic level of functioning and compliance, which is often not met at the initial stages of hospitalization/treatment initiation, such that baseline measurements are often obtained during stabilization, when (i) early treatment response has already occurred; and (ii) medications affected neurocognition.

Comorbidities, especially substance abuse and dependence, interfere with treatment outcomes in schizophrenia, typically indicating a higher disease burden and greater nonadherence. Depressive symptoms, however, have been discussed more controversially. While the majority of studies have identified comorbid depression as a predictor of poor outcome,31,108 there have also been reports of higher baseline subsyndromal depressive symptoms as positive predictors of remission.109-111

Treatment variables

Reduced odds for response and remission were most robustly associated with antipsychotic treatment nonadherence and lack of early antipsychotic benefits and, to a lesser degree, to early side effects at therapeutic doses (Table III).

Antipsychotic adherence12,112 and maintenance antipsychotic treatment26,113 are among the most replicated indicators of better outcomes. Nevertheless, psychosocial treatments in combination with antipsychotics provide even better outcomes than antipsychotics alone.114,115

The value of presence/absence of minimal improvement in psychopathology at week 1 to 4 for later response status has been confirmed as a robust predictor of presence/absence of later response status. Evidence is somewhat more robust and conclusive for chronic patients,116-125 than for FE samples.34,37,41,48,61

Environmental variables

Lower odds for remission were associated with more family conflicts66 and rural environment41 in single studies respectively (Table III), but environmental factors are relatively under-represented in current predictor analyses.

Quality and quantity of social relationships have long been a topic of investigation, with high expressed emotions having been identified as a potentially modifiable poor prognostic factor in chronic patients. Interestingly, although with FE patients a similar degree of high expressed emotions in caregivers was reported, high expressed emotions seemed to be independent of patients’ illness-related characteristics. Rather, high expressed emotions that lead to conflict, negative emotions, and social stress in chronic patients were related to caregiver coping style and signs of concern/involve.

Discussion

This review supports the idea that a focus on clinical predictors of treatment outcomes is highly insufficient to parse patients into clinically meaningful subgroups of schizophrenia. Indeed, the wide variations of response and remission rates do not only reflect the different definitions, time frames and heterogeneity of study cohorts, often including subjects with psychosis NOS or brief psychotic disorder, but also reflect the true heterogeneity of schizophrenia. Biological markers, ideally those related to the underlying pathophysiology of different subtypes of the illness and with predictive value for specific treatments, are needed to substantially move the field forward.

Nevertheless, several clinical predictors exist that clinicians can act on now. These include longer DUP, nonadherence to antipsychotics, comorbidities (especially substance-use disorder), lack of early antipsychotic response, and lack of improvement with nonclozapine antipsychotics, predicting clozapine response, likely due to a pharmacologic probe enriching samples that do not respond to classic antidopaminergic activity.

The modifiable factor, longer DUP, is one of the most replicated predictors of poor short-term and long-term therapeutic outcome in schizophrenia.6,128,129 DUP affects treatment response,39,36,78,130-132 remission,6,29,39,40-42,49,55,56,58,60,72 relapse liability,133-135 and, possibly, even long-term symptomatic outcomes.135-138 Although it has been suggested that remission becomes unlikely after a DUP of >6 months,65,135 substantial treatment effects can occur even with highly delayed
treatment initiation.\textsuperscript{74,139} Possibly related to longer DUP are also self-stigma/perceived stigma, which have been associated with lower recovery rates in chronic patients, but also with higher nonadherence, which may be a mediating factor.\textsuperscript{140}

The predictive value of the early neuroleptic response\textsuperscript{141} has been confirmed and further elaborated upon in current studies. Predictions have been extended to 1-year studies during which also the greatest degree of symptomatic improvement occurred in the first 2 to 4 weeks.\textsuperscript{142} The early response paradigm is predicated on the observation that using a <20\% reduction in the PANSS or BPRS total score, which corresponds to less than minimally improved on the CGI-I,\textsuperscript{143} has good predictive validity for nonresponse using the same or more conservative definitions of ultimate nonresponse, such as <30\%, <40\%, or <50\% reduction in the PANSS or BPRS total score. Interestingly, in contrast to chronic patients where results consistently showed that symptom improvements as early as week 1 or 2 predict ultimate response and remission,\textsuperscript{116-125} in FE samples it seems to take longer until one can declare a treatment failure.\textsuperscript{34,37,41,48,62}

This discrepancy may be due to the fact that treatment response in FE psychosis is higher,\textsuperscript{12} but also slower or, at least, that there exist subgroups with a more delayed response.\textsuperscript{143-145} Differences may also relate to the fact that brains of patients with FE schizophrenia have not been exposed to longer-term dopamine blockade in the past, that the proportion of nonresponders is lower in FE patients, and that they typically respond to lower antipsychotic doses and are more sensitive to adverse effects, especially extrapyramidal and cardiometabolic side effects.\textsuperscript{146,147} Such adverse effect sensitivity may alter response trajectories due to higher early dropouts and/or nonadherence. Nevertheless, early treatment response at week 4 (which was the first post-baseline assessment time point) was also highly predictive for response/non-response in SGA-treated antipsychotic-naïve adolescents with schizophrenia or psychosis NOS.\textsuperscript{64} Importantly, this study demonstrated that predictions need not be based on time-consuming scales, such as the PANSS or BPRS, but that less than minimally improved on the simple to use CGI-I scale was highly associated with not reaching much or very much improved scores at week 12.

Moreover, early nonresponse has also been associated with greater treatment discontinuation\textsuperscript{148,149} and non-adherence,\textsuperscript{149} which in turn is the most salient predictor of relapse.\textsuperscript{17} Further, if psychosis is indeed neurotoxic,\textsuperscript{16} it is crucial to limit the time of non-efficiently controlled psychosis as much as possible\textsuperscript{150} and alert clinicians to the low probability of treatment success even when extending the treatment duration, so that a switch should be considered. Nevertheless, to what degree a switch after early nonresponse to a first-line antipsychotic to another nonclozapine antipsychotic changes outcomes dramatically is still unclear.\textsuperscript{121}

In this context, consideration needs to be given to recurrent illness episodes as a risk factor for poorer outcome. Although relatively few studies have addressed outcome dynamics over time, response rates seem to decline gradually during the early course of schizophrenia. For example, in subjects with up to 4 psychotic episodes, 17\% failed to remit after each episode, irrespective of which episode it was.\textsuperscript{151} This finding implies that, even in previously treatment responsive subjects, each relapse bears the threat of developing treatment resistance. The different response rates across FE studies compared with multiphase studies can be in part explained by the negative selection of multi-episode/chronic schizophrenia in non-FE studies, where subjects with brief psychotic disorder are not included, nonadherent subjects, or subjects with multiple risk factors for relapses are overrepresented and the diagnostic certainty of schizophrenia vs other psychoses increases. However, the difference in response rates is also suggestive of within-subject changes in responsiveness to antipsychotics, which may reflect a neurobiological aspect of the underlying disease.\textsuperscript{16} In a naturalistic, algorithm-driven study of FE schizophrenia patients who received risperidone up to 12 weeks (4 weeks each of low, full, and then high-dose treatment) followed by olanzapine, or vice versa, treatment response rates dropped dramatically from the first trial (n=244, 74.5\%) to the second trial (n=79, 16.6\%).\textsuperscript{43} However, initiating clozapine increased response rates back to 75\% (21/28), confirming that nonresponse to nonclozapine antipsychotics predicts response to clozapine, likely due to targeting non-dopaminergic, possibly glutamatergic,\textsuperscript{152} transmission involved in the psychotic process. A CATIE data analysis has shown that patients responding well to olanzapine will likely not benefit from other non-olanzapine first-line antipsychotics.\textsuperscript{153} However, it is unclear if this may be due to greater treatment persistence that has been shown with olanzapine.\textsuperscript{154}
A decline in response has been demonstrated for multiepisode patients. In one small cohort of FE-schizophrenia (n=57), the average time to remission increased dramatically from the first episode (47 days) to the second (76 days) and third (130 days) episode respectively.\textsuperscript{155} In one small cohort of FE-schizophrenia (n=57), the average time to remission increased dramatically from the first episode (47 days) to the second (76 days) and third (130 days) episode respectively.\textsuperscript{155} Furthermore, analysis of the time courses of response in 97 subjects (including 16% with 2 relapses, and 35% with 3 or more relapses) from a multiphase, placebo-controlled relapse prevention trial indicated a slightly more rapid response in the post-relapse treatment phase until week 8, followed, however, by an earlier plateau of the response, with a small but significant difference in post-relapse PANSS scores.\textsuperscript{95} These data support the notion of within-subject changes in antipsychotic responsiveness as contributors to the slow but progressive decline in treatment response in subgroups of patients with schizophrenia. However it is unclear, which factors determine response variability after relapse. Moreover, while many subjects return to their pre-relapse functioning level with reintroduction of treatment, no predictors of nonresponse after relapse have been identified.\textsuperscript{95}

If ultimate nonremission is cause or consequence of nonresponse cannot be determined at this point, but there is clear evidence that early response and intermediate-term sustained remission are associated. For example, clinical improvement during the first month predicted 6-month remission\textsuperscript{96}; lower relative reductions of psychopathology at week 6 predicted nonremission at 2 years;\textsuperscript{91} lower positive symptom scores at 3 months predicted recovery at 2 to 3 years.\textsuperscript{52,64} A comparison of symptom domains used to define remission as predictors of functional 2-year outcome showed that the sequential number of months during which the severity criterion for remission of either positive symptoms, negative symptoms, or a combination of both was met, was significantly correlated with functioning at 2 years.\textsuperscript{156} Moreover, comparing symptom remission criteria with other factors influencing the course of illness, Bodén and colleagues\textsuperscript{157} showed a strong association of early symptomatic remission and functioning at 5-year follow-up.

A step in the direction of understanding longitudinal trajectories of outcomes in schizophrenia is the construction of pathway models for the prediction of response likelihoods based on combined qualitative and quantitative disease markers. In a pooled dataset from 6 randomized, double-blind trials comparing olanzapine to other SGAs, moderately to severely ill patients (n=1494) with chronic schizophrenia (mean illness duration=10 years) underwent post-hoc classification and regression tree (CART) analyses to determine characteristics of treatment response defined as a ≥30% reduction in total PANSS score.\textsuperscript{125} Technically, a classification analysis like CART analysis is based on binary recursive partitioning; meaning the analysis identifies nodes of decisions, at which point data are dichotomized and linked with a subsequent path leading to the next dichotomizing categorization. For each path, likelihoods can be estimated, resulting in a decision tree, in which the likelihood for each branch can be calculated. A ≥2-point score decrease in ≥2 of 5 PANSS positive items (1-delusions, 2-conceptual disorganization, 3-hallucinatory behavior, 6-suspiciousness, and 23-unusual thought content) at week 2 correctly categorized week 8 nonresponders with a predictive value of 0.75.\textsuperscript{125} However, 24% of subjects were miscategorized, pointing to the necessity of an individualized approach.

Although response, remission, and recovery are closely related, the relationship to baseline symptoms or an absolute threshold, degree of improvement, temporal extension, and considered symptom/functional domain(s) vary. Response generally focuses on the amalgam of total symptom severity, comprised of positive, negative, and general symptomatology, at one or several sequential points in time. Remission, on the other hand, includes only positive and negative symptoms and requires 6 months of no more than minimal symptomatology. Recovery requires social and educational/vocational functioning in addition to remission and both need to be sustained for 1 to 2 years, depending on the definition.\textsuperscript{19} Like the diagnostic criteria for schizophrenia, however, none of these concepts considers cognitive dysfunction, although cognition is clearly relevant for functioning.\textsuperscript{158} Nevertheless, due to the differences, predictors of response, remission, and recovery may overlap to a certain degree, but are also bound to differ.

Continued antipsychotic treatment has been examined for potentially detrimental long-term effects,\textsuperscript{89,159} but nonadherence has emerged as a reliable and addressable risk factor for lack of response and remis-
sonalize, treatment based on predicting outcomes. The modifiable risk factors for poor therapeutic outcomes that clinicians can act upon right now include longer DUP, nonadherence to antipsychotics, comorbidities (substance misuse and depression), lack of early antipsychotic response, and lack of improvement with nonclozapine antipsychotics, predicting clozapine response. It is hoped that this limited situation will improve as the pathophysiological understanding of schizophrenia increases and/or new treatments for specific aspects of schizophrenia become available, which go beyond the treatment of positive symptoms and agitation and which have mechanisms of action that go beyond modulating dopamine and serotonin transmission.

Financial disclosure: (Dr Carbon has the same disclosure information as Dr Correll due to family relationship). Dr Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza, American Academy of Child and Adolescent Psychiatry, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, Intracellular Therapies, Lundbeck, Medavante, Medscape, Merck, National Institute of Mental Health, Jansen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He has received grant support from BMS, Feinstein Institute for Medical Research, Jansen/J&J, National Institute of Mental Health, Novo Nordisk A/S and Otsuka.

Conclusions

Differences in concepts, definitions, methodology, and stages of the illness complicate the identification of both clinical and biological markers of response, remission, and recovery. Ultimately, only a better pathophysiological understanding of the different disease processes leading to the expression of schizophrenia and its exacerbation and improvement will help identify robust and generalizable predictors of therapeutic response. Until such data become available, clinicians are left with relatively little that can help stratify, let alone personalize, treatment based on predicting outcomes. The modifiable risk factors for poor therapeutic outcomes that clinicians can act upon right now include longer DUP, nonadherence to antipsychotics, comorbidities (substance misuse and depression), lack of early antipsychotic response, and lack of improvement with nonclozapine antipsychotics, predicting clozapine response. It is hoped that this limited situation will improve as the pathophysiological understanding of schizophrenia increases and/or new treatments for specific aspects of schizophrenia become available, which go beyond the treatment of positive symptoms and agitation and which have mechanisms of action that go beyond modulating dopamine and serotonin transmission.

Financial disclosure: (Dr Carbon has the same disclosure information as Dr Correll due to family relationship). Dr Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza, American Academy of Child and Adolescent Psychiatry, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, Intracellular Therapies, Lundbeck, Medavante, Medscape, Merck, National Institute of Mental Health, Jansen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He has received grant support from BMS, Feinstein Institute for Medical Research, Jansen/J&J, National Institute of Mental Health, Novo Nordisk A/S and Otsuka.

Conclusions

Differences in concepts, definitions, methodology, and stages of the illness complicate the identification of both clinical and biological markers of response, remission, and recovery. Ultimately, only a better pathophysiological understanding of the different disease processes leading to the expression of schizophrenia and its exacerbation and improvement will help identify robust and generalizable predictors of therapeutic response. Until such data become available, clinicians are left with relatively little that can help stratify, let alone personalize, treatment based on predicting outcomes. The modifiable risk factors for poor therapeutic outcomes that clinicians can act upon right now include longer DUP, nonadherence to antipsychotics, comorbidities (substance misuse and depression), lack of early antipsychotic response, and lack of improvement with nonclozapine antipsychotics, predicting clozapine response. It is hoped that this limited situation will improve as the pathophysiological understanding of schizophrenia increases and/or new treatments for specific aspects of schizophrenia become available, which go beyond the treatment of positive symptoms and agitation and which have mechanisms of action that go beyond modulating dopamine and serotonin transmission.

Financial disclosure: (Dr Carbon has the same disclosure information as Dr Correll due to family relationship). Dr Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza, American Academy of Child and Adolescent Psychiatry, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, Intracellular Therapies, Lundbeck, Medavante, Medscape, Merck, National Institute of Mental Health, Jansen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He has received grant support from BMS, Feinstein Institute for Medical Research, Jansen/J&J, National Institute of Mental Health, Novo Nordisk A/S and Otsuka.

Conclusions

Differences in concepts, definitions, methodology, and stages of the illness complicate the identification of both clinical and biological markers of response, remission, and recovery. Ultimately, only a better pathophysiological understanding of the different disease processes leading to the expression of schizophrenia and its exacerbation and improvement will help identify robust and generalizable predictors of therapeutic response. Until such data become available, clinicians are left with relatively little that can help stratify, let alone personalize, treatment based on predicting outcomes. The modifiable risk factors for poor therapeutic outcomes that clinicians can act upon right now include longer DUP, nonadherence to antipsychotics, comorbidities (substance misuse and depression), lack of early antipsychotic response, and lack of improvement with nonclozapine antipsychotics, predicting clozapine response. It is hoped that this limited situation will improve as the pathophysiological understanding of schizophrenia increases and/or new treatments for specific aspects of schizophrenia become available, which go beyond the treatment of positive symptoms and agitation and which have mechanisms of action that go beyond modulating dopamine and serotonin transmission.

Financial disclosure: (Dr Carbon has the same disclosure information as Dr Correll due to family relationship). Dr Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza, American Academy of Child and Adolescent Psychiatry, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, Intracellular Therapies, Lundbeck, Medavante, Medscape, Merck, National Institute of Mental Health, Jansen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He has received grant support from BMS, Feinstein Institute for Medical Research, Jansen/J&J, National Institute of Mental Health, Novo Nordisk A/S and Otsuka.

Conclusions

Differences in concepts, definitions, methodology, and stages of the illness complicate the identification of both clinical and biological markers of response, remission, and recovery. Ultimately, only a better pathophysiological understanding of the different disease processes leading to the expression of schizophrenia and its exacerbation and improvement will help identify robust and generalizable predictors of therapeutic response. Until such data become available, clinicians are left with relatively little that can help stratify, let alone personalize, treatment based on predicting outcomes. The modifiable risk factors for poor therapeutic outcomes that clinicians can act upon right now include longer DUP, nonadherence to antipsychotics, comorbidities (substance misuse and depression), lack of early antipsychotic response, and lack of improvement with nonclozapine antipsychotics, predicting clozapine response. It is hoped that this limited situation will improve as the pathophysiological understanding of schizophrenia increases and/or new treatments for specific aspects of schizophrenia become available, which go beyond the treatment of positive symptoms and agitation and which have mechanisms of action that go beyond modulating dopamine and serotonin transmission.

Financial disclosure: (Dr Carbon has the same disclosure information as Dr Correll due to family relationship). Dr Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza, American Academy of Child and Adolescent Psychiatry, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, Intracellular Therapies, Lundbeck, Medavante, Medscape, Merck, National Institute of Mental Health, Jansen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He has received grant support from BMS, Feinstein Institute for Medical Research, Jansen/J&J, National Institute of Mental Health, Novo Nordisk A/S and Otsuka.

Conclusions

Differences in concepts, definitions, methodology, and stages of the illness complicate the identification of both clinical and biological markers of response, remission, and recovery. Ultimately, only a better pathophysiological understanding of the different disease processes leading to the expression of schizophrenia and its exacerbation and improvement will help identify robust and generalizable predictors of therapeutic response. Until such data become available, clinicians are left with relatively little that can help stratify, let alone personalize, treatment based on predicting outcomes. The modifiable risk factors for poor therapeutic outcomes that clinicians can act upon right now include longer DUP, nonadherence to antipsychotics, comorbidities (substance misuse and depression), lack of early antipsychotic response, and lack of improvement with nonclozapine antipsychotics, predicting clozapine response. It is hoped that this limited situation will improve as the pathophysiological understanding of schizophrenia increases and/or new treatments for specific aspects of schizophrenia become available, which go beyond the treatment of positive symptoms and agitation and which have mechanisms of action that go beyond modulating dopamine and serotonin transmission.

Financial disclosure: (Dr Carbon has the same disclosure information as Dr Correll due to family relationship). Dr Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza, American Academy of Child and Adolescent Psychiatry, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, Intracellular Therapies, Lundbeck, Medavante, Medscape, Merck, National Institute of Mental Health, Jansen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He has received grant support from BMS, Feinstein Institute for Medical Research, Jansen/J&J, National Institute of Mental Health, Novo Nordisk A/S and Otsuka.
### Predicteurs cliniques de la réponse thérapeutique aux antipsychotiques dans la schizophrénie

La recherche de facteurs de prédiction des résultats cliniques dans la schizophrénie est aussi ancienne que la psychiatrie elle-même. Néanmoins, malgré de nombreuses grandes études longitudinales sur les facteurs pronostiques, très peu de ces facteurs utiles cliniquement ont été identifiés. Le but d’un traitement futur est de changer les facteurs de risque modifiables ou d’utiliser des facteurs non modifiables pour regrouper les patients dans des sous-groupes déterminants sur le plan thérapeutique. La plupart des facteurs de prédiction des résultats cliniques sont non spécifiques et/ou non modifiables. Le sexe masculin, un plus jeune âge au début de la maladie, un mauvais ajustement prémorbid et une pathologie psychiatrique sévère dès le début font partie des facteurs de pronostic non modifiables pour des chances de remission médicales. Une durée plus longue de maladie non traitée, une absence d’observance des antipsychotiques, des comorbidités (surtout l’usage de substances illicites), une absence de réponse précoc aux antipsychotiques et l’absence d’amélioration avec les antipsychotiques non clozapiniques prédés la réponse à la clozapine font partie des facteurs de risque modifiables de résultats thérapeutiques médicales sur lesquels les médecins peuvent agir. Il faut espérer que cette faible capacité prédictive s’améliorera avec une meilleure compréhension physiopathologique et le développement de traitements visant des aspects spécifiques de la schizophrénie.

### Predicteurs cliniques de la respuesta terapéutica a los antipsicóticos en la esquizofrenia

La búsqueda de predictores de resultado clínico en la esquizofrenia es tan antigua como la psiquiatría. Sin embargo, a pesar de una gran cantidad de estudios longitudinales sobre los factores pronóstico, solo se han identificado unos pocos predictores de resultado con utilidad clínica. El objetivo de las terapias a futuro es influir sobre los factores de riesgo modificables, o bien emplear los factores inmodificables para analizar a los pacientes en subgrupos terapéuticamente significativos. La mayor parte de los predictores de resultado clínico son inespecíficos y/o inmodificables. Cuando hay una baja probabilidad de remisión los predictores inmodificables incluyen al sexo masculino, la menor edad de aparición de la enfermedad, un pobre ajuste premórbido y una grave psicopatología basal. Cuando hay pobres resultados terapéuticos los factores de riesgo modificables sobre los cuales pueden actuar los clínicos incluyen la mayor duración de la enfermedad sin tratamiento, la falta de adherencia a los antipsicóticos, la comorbilidad (especialmente el abuso de sustancias), la falta de respuesta inicial a los antipsicóticos y la ausencia de mejora con antipsicóticos distintos de la clozapina, lo que puede predecir una respuesta a esta última. Se espera que esta capacidad limitada de predicción aumente en la medida que se amplíen el conocimiento y se disminuya la confusión de los tratamientos para aspectos específicos de la esquizofrenia.

26. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14:429-447.
27. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci. 2010;12:393-407.
28. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063-2071.
29. Verma S, Subramaniam M, Abdin E, Poon LY, Chong SA. Symptomatic and functional remission in patients with first-episode psychosis. Acta Psychiatr Scand. 2012;126:282-289.
30. Perkins D, Lieberman J, Gu H, et al. HGDH Research Group. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry. 2004;185:18-24.
31. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA; Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69:106-113.
32. Levine SZ, Rabinowitz J, Engel R, EtcHEL E, Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGL. Schizophr Res. 2008;98:319-322.
33. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449.
34. Gallego JA, Robinson DG, Sevy SM, et al. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry. 2011;72:1691-1696.
35. Boter H, Peuxens J, Libiger J, et al; EUFEST study group. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115:97-103.
36. Crespo-Facorro B, de la Foz VG, Ayesa-Arriola R, et al. Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP study. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:162-167.
37. Schennach-Wolff R, Jäger M, Mayr A, et al. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients: is it all about early response? Eur Neuropsychopharmacol. 2011;21:370-378.
38. Nordon C, Rouillon F, Azorin JM, Barry C, Urbach M, Falissard B. Trajectories of antipsychotic response in drug-naïve schizophrenia patients: results from the 6-month ESPASS follow-up study. Acta Psychiatr Scand. 2014;129:116-125.
Clinical research

39. Zhang HX, Shen XL, Zhou H, Yang XM, Wang HF, Jiang KD. Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: a 1 year follow-up study in Shanghai. Psychiatry Res. 2014;215:20-25.
40. Addington J, Addington D. Symptom remission in first episode patients. Schizophr Res. 2008;106:281-285.
41. Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry. 2006;67:1707-1712.
42. Emsley R, Rabinowitz J, Medori R; Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;9:129-139.
43. Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic with a retrospective data analysis. J Clin Psychiatry. 2001;62:125-276.
44. Albert N, Bertelsen M, Thorup A, et al. Predictors of recovery from psychosis Analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5 years. Schizophr Res. 2011;2005:275-266.
45. Chang WC, Hui CL, Tang JY, Wong GH, Lam MM, Chan SK, Chen EY. Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res. 2011;133:22-28.
46. Chang WC, Tang JY, Hui CL, et al. Duration of untreated psychosis: relationship with baseline characteristics and three-year outcome in first-episode psychosis. Psychiatry Res. 2012;198:360-365.
47. Crespo-Facorro B, Pelayo-Terán JM, Pérez-Iglesias R, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res. 2007;41:659-666.
48. Derks EM, Fleischhacker WW, Boter H, Peukens J, Kahn RS; EUFEST Study Group. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J Clin Psychopharmacol. 2010;30:176-180.
49. Díaz I, Pelayo-Terán JM, Pérez-Iglesias R, et al. Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. Psychiatry Res. 2013;206:181-187.
50. Gaebel W, Riebeck M, Wölwer W, et al. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophr Res. 2014;152:478-486.
51. Johnson S, Sathasivam E, Charles H, Jeyasimel V, Gauthier H, et al. Relationship between baseline characteristics and three-year outcome in first-episode psychosis. Acta Psychiatr Scand. 2007;31:1330-1336.
52. Lambert M, Naber D, Schacht A, Wagner T, Hunderer MP, Karow A, Huber CG, Suarez D, Haro JM, Novick D, Dittmann RW, Schimmelmann BG. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;118:220-229.
53. Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull. 2010;36:624-632.
54. Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J Clin Psychopharmacol. 2010;30:446-449.
55. Malhi GS, Nolen WA, Schmitz N, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med. 2006;36:649-658.
56. Pelayo-Terán JM, Díaz FJ, Pérez-Iglesias R, et al. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychol Med. 2014;44:37-50.
57. Petersen L, Thorup A, Oglienschlaeger J, et al. Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder patient: 2-year follow-up of the OPUS trial. Can J Psychiatr. 2008;53:660-670.
58. Saravanan B, Jacob KS, Johnson S, Prince M, Bhugra D, David AS. Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathology. Br J Psychiatry. 2010;196:454-459.
59. Selten JP, Veen ND, Hoek HW, et al. Early course of schizophrenia in a representative Dutch incidence cohort. Schizophr Res. 2007;97:79-87.
60. Simonsen E, Fries S, Ojbjergsdam S, et al. Early Identification of non-remission in first-episode psychosis in a two-year outcome study. Acta Psychiatr Scand. 2010;122:375-383.
61. Staufer VL, Case M, Kinon BJ, et al. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res. 2011;187:42-48.
62. Sten十万berg-Olesen M, Jeppesen P, Pagsberg AK, et al. Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturally treated with second-generation antipsychotics. J Child Adolesc Psychopharmacol. 2013;23:665-675.
63. Üçok A, Serbest S, Kandermi PE. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res. 2011;189:33-37.
64. Vanturita T, Subotnik KL, Guadagni H, et al. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res. 2011;132:18-23.
65. Wunderlin K, Sytma S, Nienhuis FJ, Wiersma D. Clinical recovery in first-episode psychosis. Schizophr Res. 2010;35:222-227.
66. Galderisi S, Bucci R, Üçok A, Peuskens J. No gender differences in social outcome in patients suffering from schizophrenia. Eur Psychiatry. 2012;27:406-408.
67. Wunderlin K, Nieboer RM, Wiersma D, Sytma S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70:913-920.
68. Clemmensen L, Vernal DH, Steinhausen HC. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry. 2012;12:150.
69. Nielsen J, Nielsen RE, Correll C. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register study. J Clin Psychopharmacol. 2012;32:678-683.
70. Tefferra S, Shibire T, Fekadu A, et al. Five-year clinical course and outcome of schizophrenia in Ethiopia. Schizophr Res. 2012;136:137-142.
71. Semiz UB, Cetin M, Basoglu C, et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1330-1336.
72. Jeppesen P, Petersen L, Thorup A, et al. The association between premorbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med. 2008;38:1157-1166.
73. Kurilhara T, Kato M, Reverger R, Tirta IG. Remission in schizophrenia: a community-based 6-year follow-up study in Bali. Psychiatry Clin Neurosci. 2011;65:476-482.
74. Thirthalli J, Channaveeracharhi NK, Subbakrishna DK, Cottler LB, Varghese M, Gangadhar BN. Prospective study of duration of untreated psychosis and outcome of never-treated patients with schizophrenia in India. Indian J Psychiatry. 2011;53:319-323.
75. Rabinowitz J, Werbeloff N, Caers I, et al. Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials. J Clin Psychiatry. 2014;75:e308-e316.
76. Levine SZ, Leucht S. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. Schizophr Res. 2014;156:107-114.
77. Olesen TK, Moe LC, Vibe-Hansen L, Johannessen JO. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode schizophrenia. Schizophr Res. 2000;45:1-9.
78. Bottlender R, Sato T, Jäger M, et al. The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res. 2003;62:37-44.
79. Jönsdóttir H, Opjordsmoen S, Birkenaes AB, et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2013;127:23-33.
80. Thorup A, Albert N, Bertelsen M, et al. Gender differences in first-episode psychosis at 5-year follow-up-two different courses of disease? Results from the OPUS study at 5-year follow-up. Eur Psychiatry. 2014;29:44-51.
81. Jin J, Sklar GE, Oh VMS, Li S. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag. 2008;4:269-286.
82. Spellman J, Riedel M, Schennach R, et al. One-year functional outcomes of naturally-ill treated patients with schizophrenia. Psychiatry Res. 2012;198:378-385.
83. Rabinowitz J, Harvey PD, Eerdekens M, Davidson M. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006;189:31-35.
84. Wilder J. The law of initial value in neurology and psychiatry: Facts and problems. J Nerv Ment Dis. 1957;125:73-86.
85. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission and relapse of symptoms and functional remission and adequate subjective well-being in 2690 patients with schizophrenia. J Clin Psychiatry. 2006;67:1690-1697.
86. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry. 1991;48:978-986.
87. Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry. 1991;148:151-156.
88. Fousiai G, Remington G. Negative symptoms in schizophrenia: avolition and Ocam's razor. Schizophr Bull. 2010;36:359-369.
89. Fervaha G, Fousiai G, Agid O, Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr Scand. 2014;130:290-299.
90. Bowie CR, Leung WW, Reichenberg A, et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63:505-511.
91. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137:147-150.
92. Schimmelmann BG, Conus P, Cotton S, McGorry PD, Lambert M. Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res. 2007;95:1-8.
93. Amminger GP, Henry LR, Harrigan SM, et al. Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr Res. 2011;131:112-119.
94. Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry. 2012;73:e541-e547.
95. Emsley R, Nuanhaj I, Hough D, Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res. 2012;138:29-34.
96. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006;31:2033-2046.
97. Gaiderisi S, Davidson M, Kahn RS, et al. EUFEST Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophr Res. 2009;115:104-114.
98. Gold S, Arndt S, Nopoulos P, O'Leary DS, Andreasen NC. Longitudinal Study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry. 1999;156:1342-1348.
99. Stirling J, White C, Lewis S, et al. Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr Res. 2003;65:75-86.
100. Miller P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognitive and negative symptoms on functional outcome in schizophrenia. Arch Gen Psychiatry. 2005;62:495-506.
101. Tabarés-Seisdedos R, Balanzá-Martínez V, Sánchez-Moreno J, et al. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord. 2008;109:286-299.
102. Kurtz MM. Neurocognition as a predictor of response to evidence-based psychosocial interventions in schizophrenia: what is the state of the evidence? Clin Psychol Rev. 2011;31:663-672.
103. Jordan G, Lutgens D, Joobr R, Lepage M, Iyer S, Malla A. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry 2014;75:e566-e572.
104. Allott K, Liu P, Proffitt TM, Killackey E. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Schizophr Res. 2011;125:221–235.
105. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizophrenia/schizoaffective disorder. Am J Psychiatry. 2002;159:1018-1028.
106. Zipursky RB. Why are the outcomes in patients with schizophrenia so poor? J Clin Psychiatry. 2014;75(suppl 2):20-24.
107. Thoma P, Daum I. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatr Clin Neurosci. 2013;67:367-380.
108. Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007;90:186-197.
109. Eton WW, Thara R, Federman E, et al. Remission and relapse in schizophrenia: the Madras Longitudinal Study. J Nerv Ment Dis. 1998;186:357-363.
110. Oosthuizen P, Emsley RA, Roberts MC, et al. Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia. Schizophr Res. 2002;58:247-252.
111. Haro JM, Novick D, Bertsch J, Karagianis J, Dossenbach M, Jones PB. Cross-national clinical and functional remission rates: Worldwide Schizophrenia-Outcome Health Outcomes (W-SOHO) study. Br J Psychiatry. 2011;199:194-201.
112. Casieiro O, Pérez-Iglesias R, Mata I, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012;46:1099-1105.
113. Emsley R, Chiliza B, Aslam L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148:117-121.
114. Menezes NM, Arenovitch T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med. 2006;36:1349-1362.
115. Huhn M, Tardy M, Spinelli LM, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic review of meta-analyses. JAMA Psychiatry, 2014;71:706-715.
116. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160:2063-2065.
117. Leucht S, Shamsi SA, Busch R, Kisling W, Kane JM. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr Res. 2008;101:312-319.
118. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34:1163-1171.
119. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102:230-240.
120. Jäger M, Schmauss M, Laux G, et al. Early improvement as a predictor of remission and response in schizophrenia: results from a naturalistic study. Eur Psychiatry. 2009;24:501-506.
121. Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35:581-590.
122. Hatta K, Otachi T, Sudo Y, et al. JAST Study Group. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-episode schizophrenia. Schizophr Res. 2011;128:127-135.
123. Schenck R, Riesbeck M, Mayr A, et al. Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients? Acta Psychiatr Scand. 2013;127:474-481.
124. van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res. 2009;107:13-21.
Clinical research

125. Ruberg SJ, Chen L, Stauffer V, et al. Identification of early changes in specific symptoms that predict long-term response to atypical antipsychotics in the treatment of patients with schizophrenia. *BMC Psychiatry*. 2011;11:23.

126. Butzlaff RL, Hooley JM. Expressed emotion and psychiatric relapse: a meta-analysis. *Arch Gen Psychiatry*. 1998;55:547-52.

127. Koutra K, Vgontzas AN, Lionis C, Trilla S. Family functioning in first-episode psychosis: a systematic review of the literature. *Soc Psychiatry Psychiatr Epidemiol*. 2014;49:1023-1036.

128. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review, meta-analysis. *Am J Psychiatry*. 2005;162:1785-1804.

129. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. *Arch Gen Psychiatry*. 2005;62:975-983.

130. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DJ, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. *Am J Psychiatry*. 1992;149:1183-1188.

131. Drake RJ, Haley CJ, Akhtar S, Lewis SW. Causes and consequences of duration of untreated psychosis in schizophrenia. *Br J Psychiatry*. 2000;177:511-515.

132. Ucok A, Polat A, Genç A, Cakir S, Turan N. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. *J Psychiatr Res*. 2008;43:163-168.

133. Ucok A, Polat A, Cakir S, Genç A. One year outcome in first episode schizophrenia. *Predictors of relapse*. *Arch Psychiatry Clin Neuosci*. 2006;256:37-43.

134. Czecknicki A, Cichocki L, Kalisz A, Błaszczynski P, Adamczyk P, Franciszyk-Glita J. Duration of untreated psychosis (DUP) and the course of schizophrenia in a 20-year follow-up study. *Psych Res*. 2014;219:420-425.

135. Czecknicki A, Hanuszkiwicz I, Polczyk R, Bielarska A. Prognostic value of duration of untreated psychosis in long-term outcome of schizophrenia. *Med Sci Monit*. 2011;17:CR277-2CR83.

136. Harris MG, Henly LP, Harrigan SM, et al. The relationship between duration of untreated psychosis and outcome: an eight year prospective study. *Schizophr Res*. 2005;79:85-93.

137. White C, Stirling J, Hopkins R, et al. Predictors of 10-year outcome of first-episode psychosis. *Psychol Med*. 2009;39:1447-1456.

138. Alvarez-Jiménez M, Gleenon JF, Henly LP, et al. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode schizophrenia. *Schizophr Res*. 2011;125:236-246.

139. Tirupati NS, Rangaswamy T, Raman P. Duration of untreated psychosis and treatment outcome in schizophrenia patients untreated for many years. *Aust NZ J Psychiatry*. 2004;38:339-343.

140. Gerlinger G, Hauser M, De Hert M, et al. Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlations, impact and interventions. *World Psychiatry*. 2013;12:155-164.

141. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. *Arch Gen Psychiatry*. 2003;60:1228-1235.

142. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. *Biol Psychiatry*. 2005;57:1543-1549.

143. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. *Am J Psychiatry*. 2005;62:1743-1749.

144. Jäger M, Riedel M, Messer T, et al. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenia disorders. *Eur Arch Psychiatry Clin Neurosci*. 2007;257:47-53.

145. Jäger M, Riedel M, Obermeier M, et al. Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients. *Schizophr Res*. 2010;118:183-188.

146. Zhang JP, Gallego J, Robinson D, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs first-generation antipsychotics in first episode schizophrenia: a systematic review and meta-analysis. *Int J Neuropsychopharmacol*. 2013;16:1205-1218.

147. Correll CJ, Lenz C, Malhotra AK. Antipsychotic drugs and obesity. *Trends Mol Med*. 2011;17:97-107.

148. Kion SJ, Ascher-Svanum H, Adams DH, Chen L. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials. *J Clin Psychopharmacol*. 2008;28:544-549.

149. Faries D, Ascher-Svanum H, Phillips G, et al. Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial. *BMC Med Res Methodol*. 2012;12:142.

150. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. *J Clin Psychiatry*. 2007;68:654-661.

151. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. *Schizophr Bull*. 1998;24:75-85.

152. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. *Biol Psychiatry*. 2014;75:e1-3.

153. Clark SL, Adkins DE, van den Oord EJ. Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. *Schizophr Res*. 2011;132:114-120.

154. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*. 2005;353:1209-1223.

155. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. *J Clin Psychiatry*. 1996;57(suppl 9):5-9.

156. Cassidy CM, Norman R, Manchanda R, Schmitz N, Mailia A. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. *Schizophr Bull*. 2010;36:1001-1008.

157. Bodén R, Sundström J, Lindström E, Lindström L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. *Schizophr Res*. 2009;107:232-237.

158. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. *Am J Psychiatry*. 2000;157:549-559.

159. Ho BC, Andreasen NC, Zeibell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. *Arch Gen Psychiatry*. 2011;68:128-137.

160. Kane JM, Kishimoto T, Correll CU. Factors contributing to non-adherence in patients with psychotic disorders. *World Psychiatry*. 2013;12:216-226.

161. Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. *Am J Psychiatry*. 2013;170:609-615.

162. Emsley R, Chiliza B, Asmal L, et al. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. *Schizophr Res*. 2014;158:230-235.